Release Date: March 20, 2015 | Expiration Date: March 20, 2016
Media: Print with online posttest, evaluation, and request for credit
This CME activity features data from selected presentations on antiangiogenic agents from the 2015 Gastrointestinal Cancers Symposium, chosen for their impact on current clinical practice or because they lay the groundwork for further investigations. Topics include the new approaches to chemotherapy and targeted therapy with antiangiogenic agents for the treatment of gastrointestinal cancers, including colorectal cancer and hepatocellular carcinoma.
Instructions For This Activity & Receiving Credit
This activity is directed toward medical oncologists who treat patients with gastrointestinal malignancies. Fellows, nurses, physician assistants, nurse practitioners, and other healthcare providers are also invited to participate.
Learning ObjectivesAfter participating in this CME activity, learners should be better prepared to:
- Identify key outcomes of selected clinical trials from the 2015 Gastrointestinal Cancers Symposium
- List major adverse events experienced by patients in selected clinical trials from the 2015 Gastrointestinal Cancers Symposium
- Describe the study design of selected clinical trials from the 2015 Gastrointestinal Cancers Symposium
Allison A. Muller, PharmD, DABAT
Disclosure: No relevant financial relationships with commercial interests to disclose.
The American Journal of Hematology/ Oncology® Editorial Board
Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/Research Support: Genentech/Roche, Pfizer, Puma, Inc. (clinical trial support contracted to University of Southern California); Consultant: Eisai, Novartis
Myron Czuczman, MD
Professor of Oncology
Chief, Lymphoma/Myeloma Service
Department of Medicine
Head, Lymphoma Translational Research Laboratory
Department of Immunology
Roswell Park Cancer Institute
Disclosure: Other Support: Advisory Board: Algeta, Celgene Corporation, Teva, Boehringer-Ingelheim, Mundipharma
The staff of Physicians' Education Resource (PER®), LLC (Ann C. Lichti, CCMEP, Beth Cameron, PhD, Michael Perlmutter, MS, PharmD, and Megan O'Connell) as well as the editorial staff of The American Journal of Hematology/Oncology® (Devera Pine) have no relevant financial relationships with commercial interests to disclose.
Staff/Planner Disclosures and Conflict of Interest Resolution
In accordance with ACCME's Standards for Commercial SupportSM, PER® resolved all conflicts of interest (COI) prior to the release of this CME activity using a multistep process.
Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is funded by Physicians' Education Resource®.
Off-Label Disclosure and DisclaimerThis CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
DisclaimerThe opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Hardware And Software RequirementsSupported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise